Welcome to our dedicated page for Ascendis Pharma news (Ticker: ASND), a resource for investors and traders seeking the latest updates and insights on Ascendis Pharma stock.
Ascendis Pharma A/S reports developments as a global biopharmaceutical company applying its TransCon technology platform to new therapies in endocrinology, rare disease and oncology. News commonly centers on TransCon CNP, also known as navepegritide, including YUVIWEL for pediatric achondroplasia, as well as TransCon hGH combination data and growth-disorder clinical programs.
Recurring company updates also include financial results and business updates, U.S. regulatory and commercialization milestones, patient-access programs, and capital-structure actions such as convertible senior note activity. Corporate news also documents the completed transition from American Depositary Shares to ordinary shares trading on Nasdaq under ASND.
Ascendis Pharma (Nasdaq: ASND) will present Week 104 data from its pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia at the ISDS 2026 meeting in Toronto, held August 26–29, 2026. The oral presentation, titled “Improved Growth and Physical Functioning in Children with Achondroplasia Treated with Navepegritide in the ApproaCH Trial Open-Label Extension,” is scheduled for Friday, August 28, 10:00–10:15 a.m., and will be delivered by Carlos Bacino, M.D.
Ascendis will also present a poster analyzing number needed to harm for injection site reactions when indirect treatment comparison is not suitable. TransCon CNP (marketed as YUVIWEL) received U.S. FDA approval in February 2026 for increasing linear growth in certain pediatric achondroplasia patients, and its Marketing Authorisation Application is under review by the European Medicines Agency, with a decision expected in the fourth quarter of 2026.
Ascendis Pharma (Nasdaq: ASND) reported Q2 2026 total product revenue of €315 million, up 105% year over year, led by YORVIPATH with €252 million, SKYTROFA with €55 million, and YUVIWEL with €8 million. Total revenue reached €339 million.
Operating profit was €220 million (65% margin), versus a €53 million operating loss a year earlier, driven by product revenue growth and sale of a Rare Pediatric Disease Priority Review Voucher for €158 million net. Net profit was €207 million, or €2.83 per diluted share; non-IFRS net profit was €61 million.
Cash and cash equivalents rose to €812 million, including €56 million used for share repurchases and RSU settlements. Ascendis completed the optional redemption and conversion of all $575 million 2.25% Convertible Senior Notes due 2028, settling €719 million of related liabilities to equity, and was added to multiple Russell U.S. Indexes.
Ascendis Pharma (Nasdaq: ASND) will report its second quarter 2026 financial results and provide a business update on Thursday, August 13, 2026, before U.S. market open. The company will host a conference call and live webcast at 8:00 a.m. Eastern Time, with access and a 30‑day replay available via the Investors & News section of its website.
Ascendis Pharma (Nasdaq: ASND) reported Week 78 results from the Phase 2 COACH trial of combination therapy with once-weekly TransCon CNP and TransCon hGH in children with achondroplasia, showing mean annualized growth velocity around 7.7 cm/year and sustained improvements in achondroplasia height Z-scores, with safety and tolerability consistent with monotherapies.
The company also announced Week 104 data from the pivotal ApproaCH trial of TransCon CNP monotherapy, demonstrating durable gains in height, body proportionality, and lower-limb alignment over two years, and high treatment retention in the long-term AttaCH extension. Target enrollment for the pivotal reACHin infant trial has been completed, and an EU decision on TransCon CNP monotherapy is anticipated in Q4 2026. In the U.S., more than 170 unique YUVIWEL patient enrollments were recorded by June 30, 2026, with over 65% approved for reimbursement.
Ascendis Pharma (Nasdaq: ASND) reported Week 104 data from the pivotal ApproaCH trial of once-weekly TransCon CNP in 84 children with achondroplasia. Radiographic assessments showed continued improvements in tibial-femoral angle (TFA) and TFA Z-scores through two years, greater in children with preexisting genu varum, with stable fibula-to-tibia ratios and a generally well-tolerated safety profile.
Ascendis (Nasdaq: ASND) has been added to multiple Russell U.S. indexes, including the Russell 3000, Russell 1000, Russell 2500 and Russell Midcap, effective after the U.S. market close on June 26, 2026.
These indexes cover most investable U.S. equities and serve as key benchmarks, with about $11.8 trillion in assets benchmarked to Russell U.S. Indexes as of December 31, 2024.
Ascendis (Nasdaq: ASND) will present new clinical data in achondroplasia at ICCBH 2026 in Montreal, June 27-30. Presentations cover Week 104 lower-extremity alignment results from the pivotal ApproaCH Trial of TransCon CNP and 52-week Phase 2 COACH Trial combination data with TransCon CNP and TransCon hGH.
TransCon CNP, approved by the FDA as YUVIWEL in February 2026, is under EMA review for children with achondroplasia. TransCon hGH (SKYTROFA) is approved for growth hormone deficiency and remains investigational in achondroplasia.
Ascendis Pharma (Nasdaq: ASND) reported Week 182 Phase 3 PaTHway data showing long-term TransCon PTH (palopegteriparatide) treatment sustained efficacy and safety in adults with hypoparathyroidism.
86% met a multi-component endpoint, 89% completed the 3.5-year trial, kidney function and quality-of-life measures improved and remained stable, and no anti-PTH antibodies emerged.
Ascendis Pharma (Nasdaq: ASND) reported 5-year Phase 2 PaTH Forward data showing TransCon PTH (palopegteriparatide) maintained normalized calcium, improved kidney function, and supported quality of life in adults with hypoparathyroidism.
At Week 266, 82% met the multi-component response, 95% completed treatment, and safety remained generally well-tolerated.
Ascendis (Nasdaq: ASND) will present new data from its rare endocrine disease programs at ENDO 2026 in Chicago, June 13–16, 2026.
Presentations cover hypoparathyroidism, achondroplasia, and pediatric growth hormone deficiency, including Phase 3 PaTHway and Phase 2 COACH trial results and registry data on lonapegsomatropin.